Use of Lipid-modifying Therapy and LDL-C Goal Attainment in a High-Cardiovascular-Risk Population in the Netherlands.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

This study investigates lipid-modifying therapy (LMT) and LDL-C goal attainment in a real-world, high-cardiovascular-risk population in the Netherlands.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Ther

Title: Clinical therapeutics

Publisher: Elsevier BV

ISSN (Electronic): 1879-114X

ISSN (Print): 0149-2918

Publication date (Electronic): Apr 2017

Volume: 39

Issue: 4

Affiliations

[1 ] PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands. Electronic address: Josine.kuiper@pharmo.nl.

[2 ] Regeneron, Tarrytown, New York.

[3 ] PHARMO Institute for Drug Outcomes Research, Utrecht, the Netherlands.

[4 ] Sanofi, Bridgewater, New Jersey.

[5 ] Sanofi, Gouda, the Netherlands.

Article

Publisher Item ID: S0149-2918(17)30175-3

DOI: 10.1016/j.clinthera.2017.03.001

PubMed ID: 28347514

SO-VID: cd1fb7d7-28ba-4fce-928e-7b1a16db7b3d

History

Keywords: cardiovascular disease,prevention,statin,LDL-C

Data availability:

Keywords: cardiovascular disease, prevention, statin, LDL-C

Comments

Comment on this article

scite_

Cited by 20

See all cited by